UroGen Pharma Ltd

NASDAQ:URGN  
5.44
+0.27 (+5.22%)
Earnings Announcements

UroGen Pharma Reports First Quarter 2022 Financial Results

Published: 05/10/2022 13:30 GMT
UroGen Pharma Ltd (URGN) - Urogen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments.
Q1 Loss per Share $1.25.
Q1 Earnings per Share View $-1.33 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $17.42 Million
Adjusted EPS is expected to be -$1.23

Next Quarter Revenue Guidance is expected to be $20.78 Million
Next Quarter EPS Guidance is expected to be -$1.18

More details on our Analysts Page.